

## Frequently Asked Questions

### **How do I contact CardioDynamics Investor Relations?**

Please contact our investor relations department:

Bonnie Ortega  
CardioDynamics International Corporation  
6175 Nancy Ridge Drive, Suite 300  
San Diego, California 92121

Phone: (800) 778-4825, Ext. 1005 (office)  
Fax: (858) 535-0055 (fax)  
Email: [ir@cardiodynamics.com](mailto:ir@cardiodynamics.com)

[Jump to Information Request Page](#)

### **Where is CardioDynamics' stock traded?**

CardioDynamics' common stock is traded on the NASDAQ National Market System under the symbol CDIC.

### **What is CardioDynamics' fiscal year?**

CardioDynamics' fiscal year ends on November 30th.

### **When will CardioDynamics announce its quarterly financial results?**

CardioDynamics usually releases its quarterly financial results the third week following the end of each quarter except the fourth quarter and fiscal year end which usually takes place the third week in January. A conference call and webcast take place after close of market to discuss the financial results.

### **How does someone buy CardioDynamics stock?**

CardioDynamics stock can be bought or sold through a financial institution that provides brokerage services. We do not offer direct purchase of our stock.

### **Who is CardioDynamics' transfer agent and how does a registered stockholder obtain account information?**

Our transfer agent is:  
American Stock Transfer & Trust Corporation

59 Maiden Lane  
New York, NY 10038  
Tel: 800-937-5449  
Tel: 718-921-8124  
Fax: 718-236-2641  
Website: [www.amstock.com](http://www.amstock.com)

### **What are the details of the recent 10b5-1 Trading Plan?**

In May 2004, members of CardioDynamics' executive management team entered into formal 10b5-1 Trading Plans . A 10b5-1 Trading Plan is a pre-arranged plan for trading company stock in accordance with Securities and Exchange Commission Rule 10b5-1. Under such plans, the executive officer or director does not retain any discretion over the execution of such transactions, which a broker executes in a predetermined manner, typically over a period of time. Such a plan is used to achieve portfolio diversification and liquidity objectives while avoiding concerns about initiating stock transactions when aware of nonpublic information. Pre-arranged trading plans can also benefit shareholders by reducing or eliminating the market disruption that could otherwise occur if executive officers and directors were to conduct all of their transactions in relatively brief periods.

Neither the Company nor the executives were aware of any material nonpublic information at the time these plans were established. The plans were designed to generally mirror the executive's historical open window trading patterns. Trades under each of the plans may not occur until after June 25, 2004 and no trades may be made under the plans during CardioDynamics' quarterly restricted periods for insider transactions.

The total number of shares proposed to be sold under Rule 10b5-1 plans by these six individuals is less than 300,000 shares, representing approximately 7% of their anticipated aggregate beneficial holdings at the time of sale and less than one percent of the outstanding shares. The transactions are planned to occur between June and the end of 2004. The Company anticipates that, as permitted by Rule 10b5-1 and its trading policies, other executive officers and directors may establish such plans in the future.

---

top of page